The over-arching goal of this project is to determine the regulatory role of anti-inflammatory molecules on neuroinflammatory activities and beta-amyloidosis (A? aggregation and deposition in brain) in rodent models of Alzheimer's disease (AD). Our previous studies on a double transgenic mouse expressing familial AD mutants of ?-amyloid precursor protein (APP) and glial fibrillar acidic protein promoter-driven murine CCL2 and APP transgenic mice lacking interferon-? receptor type I demonstrated that chemokines and pro-inflammatory cytokines are critically involved in progression of beta-amyloidosis and microgliosis in brain. Accordingly, glatiramer acetate immunization, a known anti-inflammatory therapy, reduced beta-amyloidosis, enhanced neurogenesis, and improved cognitive function in APP mice. In addition, specific anti-inflammatory cytokines (interleukin-4;IL-4, IL-10, among others) can directly induce anti-inflammatory and neuroprotective phenotype of microglia. Thus, we hypothesize that anti-inflammatory cytokines (IL-4 or IL-10, among others) may induce suppression of neuroinflammation and beta-amyloidosis-related cognitive dysfunction in vivo. Our preliminary studies support this hypothesis, since chronic expression of neutralizing CCL2 mutant (7ND, lacking the first 7 amino acid sequence) suppresses microgliosis and A? oligomer accumulation, and improves cognitive function in a double transgenic mice (APP/PS1) expressing APP and presenilin-1 (PS1). Using adeno-associated virus (AAV)-mediated gene delivery system for expressing IL-4, IL-10, 7ND in APP/PS1 mice at pre- and post- symptomatic stages of memory dysfunction, we will ask the following questions: 1) Does 7ND, IL-4, or IL-10 suppress astro/microgliosis? If so, is it restricted to hippocampal region or both in cortex and hippocampus?;2) Does IL-4 or IL-10 induce dendritic-like (CD11c+) microglia? If so, is it neuroprotective?;3) Does IL-4 or IL- 10 induce inflammation regulatory molecules (CD200, CD200R)?;4) Does IL-4 or IL-10 reduce beta- amyloidosis? If so, is it specific to compact plaques, diffuse plaques, or A? oligomers?;5) Does IL-4 or IL-10 enhance neurogenesis? If so, is it accompanied with enhanced newly synthesized neurons or astrocytes? 6) Does IL-4 or IL-10 enhance synaptogenesis? If so, is it specific to presynaptic or postsynaptic molecules?;and 7) Does 7ND, IL-4 or IL-10 enhance memory formation after injection of lower doses of AAV? If so, is it effective in both pre-symptomatic and post-symptomatic stages? This proposal is significant, since to the best of our knowledge, therapeutic efficacy of 7ND, IL-4 or IL-10 gene delivery has never been tested in APP or APP/PS1 mice in vivo. These approaches may have significant implication for immunotherapy of AD and other neurodegenerative diseases.

Public Health Relevance

Alzheimer's disease (AD) is a leading neurological disease that affects more than 4 million people in the US, who are left without effective therapy. Using the established the genetically engineered mouse model of AD (APP/PS1 mice), we will characterize the beneficial effect of anti-inflammatory cytokines (interleukin-4 and 10) and neutralizing chemokine mutant (for CCL2), on beta-amyloidosis and cognitive function inAPP/PS1 mice. These approaches may have therapeutic implication for AD and other neurodegenerative diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AG032600-01A1
Application #
7588274
Study Section
Clinical Neuroimmunology and Brain Tumors Study Section (CNBT)
Program Officer
Refolo, Lorenzo
Project Start
2009-02-01
Project End
2011-01-31
Budget Start
2009-02-01
Budget End
2010-01-31
Support Year
1
Fiscal Year
2009
Total Cost
$189,338
Indirect Cost
Name
University of Nebraska Medical Center
Department
Pharmacology
Type
Schools of Medicine
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Varnum, Megan M; Kiyota, Tomomi; Ingraham, Kaitlin L et al. (2015) The anti-inflammatory glycoprotein, CD200, restores neurogenesis and enhances amyloid phagocytosis in a mouse model of Alzheimer's disease. Neurobiol Aging 36:2995-3007
Woodbury, Maya E; Freilich, Robert W; Cheng, Christopher J et al. (2015) miR-155 Is Essential for Inflammation-Induced Hippocampal Neurogenic Dysfunction. J Neurosci 35:9764-81
Kiyota, T; Ingraham, K L; Swan, R J et al. (2012) AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. Gene Ther 19:724-33
Varnum, Megan M; Ikezu, Tsuneya (2012) The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch Immunol Ther Exp (Warsz) 60:251-66
Lan, Xiqian; Kiyota, Tomomi; Hanamsagar, Richa et al. (2012) The effect of HIV protease inhibitors on amyloid-? peptide degradation and synthesis in human cells and Alzheimer's disease animal model. J Neuroimmune Pharmacol 7:412-23
Lan, Xiqian; Xu, Jiqing; Kiyota, Tomomi et al. (2011) HIV-1 reduces Abeta-degrading enzymatic activities in primary human mononuclear phagocytes. J Immunol 186:6925-32
Kiyota, Tomomi; Ingraham, Kaitlin L; Jacobsen, Michael T et al. (2011) FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders. Proc Natl Acad Sci U S A 108:E1339-48
Freilich, Robert W; Ikezu, Tsuneya (2011) Neuroimmune pharmacology as a sub-discipline of medical neuroscience in the medical school curriculum. J Neuroimmune Pharmacol 6:41-56
Flaherty, Daniel P; Kiyota, Tomomi; Dong, Yuxiang et al. (2010) Phenolic bis-styrylbenzenes as ?-amyloid binding ligands and free radical scavengers. J Med Chem 53:7992-9
Kiyota, Tomomi; Okuyama, Satoshi; Swan, Russell J et al. (2010) CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J 24:3093-102

Showing the most recent 10 out of 13 publications